In CRSwNP, mepolizumab effectively suppresses IL-5-mediated eosinophil activation, yet persistent IL-33/TSLP signaling in local microenvironments may drive residual inflammation, leading to partial therapeutic responses. The gene discussed is IL33; the disease is chronic rhinosinusitis with nasal polyps.